FindTrial
Sign In

Comparing Two Doses of Sugammadex for Reversal of Muscle Relaxant Rocuronium in patients undergoing general anaesthesia

Comparison of Two Different Doses of Sugammadex for Reversal of Rocuronium Induced Neuromuscular Blockade - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094869
Enrollment
66
Registered
2025-09-16
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z418- Encounter for other procedures forpurposes other than remedying health state

Interventions

Intervention1: Sugammadex 1mg per kg or 2 mg per kg: Sugammadex administered in two different doses, at 1mg per lg and 2mg per kg intravenous. Administered at TOF count 4 and TOFR less than 0.3 durin

Sponsors

Dr Annie Paul
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA physical status 1 or 2 Surgeries under general anaesthesia with controlled ventilation for equal or greater than 40 minutes duration

Exclusion criteria

Exclusion criteria: Known hypersensitivity to study drugs Neuromuscular disorders Medications altering effects of NMBA

Design outcomes

Primary

MeasureTime frame
Time from administration of Sugammadex to achieving TOFR greater than 0.9Timepoint: 18 months—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactDr Vibhuti Sharma

Vardhman Mahavir Medical College and Safdarjung Hospital

vibhuti411@gmail.com9810903924

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026